GTx to Raise $47.5M to Develop Cancer Drugs
By Mari Serebrov
Friday, June 24, 2011
With its sights set on pushing two cancer candidates through the pipeline, GTx Inc. is looking to a $47.5 million public offering to fund Phase III development of Ostarine and Phase II trials for Capesaris.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.